Multiple cancer-related signaling and apoptotic pathway components

Multiple cancer-related signaling and apoptotic pathway components is a broad, non-specific designation used to describe a collection of molecular entities that govern tumor cell growth, survival, and programmed death. This category encompasses several critical signaling axes, including the PI3K/AKT/mTOR, MAPK/ERK, and JAK/STAT pathways, which are frequently dysregulated in various malignancies (Source: PubMed, PMC4519100). It also includes the machinery of apoptosis, such as the Bcl-2 family of proteins and the caspase cascade, which serve as the final executioners of cell death (Source: NIH, National Cancer Institute). Drugs associated with this "target" are typically multi-targeted agents, such as certain phytochemicals (e.g., curcumin) or broad-spectrum kinase inhibitors, that aim to disrupt the redundant survival networks of cancer cells. Because this term refers to a functional group of proteins rather than a single, well-defined receptor or enzyme, it is considered a descriptive pharmacological category rather than a specific therapeutic target. This multi-node intervention strategy is intended to reduce the likelihood of drug resistance, though it often complicates the identification of precise mechanisms of action and increases the risk of off-target effects.

Other names

Cancer signaling pathwaysApoptotic signaling componentsMulti-target signaling networks

Simultaneous modulation of multiple signaling nodes and pro-apoptotic factors to inhibit tumor growth and induce cell death.